{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:43:14Z","timestamp":1794112994571,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS119873"],"award-info":[{"award-number":["NS119873"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neurot.2025.e00732","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:12:04Z","timestamp":1756984324000},"page":"e00732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["PROTACs therapeutically target the polyglutamine androgen receptor in spinal and bulbar muscular atrophy models"],"prefix":"10.1016","volume":"22","author":[{"given":"Agamjot","family":"Sangotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satya L.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis J.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Merry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Grunseich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00732_bib1","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1093\/brain\/awp258","article-title":"Clinical features of spinal and bulbar muscular atrophy","volume":"132","author":"Rhodes","year":"2009","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurot.2025.e00732_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","article-title":"Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy","volume":"352","author":"Spada","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00732_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0960-8966(99)00132-7","article-title":"Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families","volume":"10","author":"Mariotti","year":"2000","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.neurot.2025.e00732_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","article-title":"Polyglutamine repeats in neurodegenerative diseases","volume":"14","author":"Lieberman","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.neurot.2025.e00732_bib5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-019-00790-9","article-title":"Molecular mechanisms and therapeutics for SBMA\/Kennedy's disease","volume":"16","author":"Arnold","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00732_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14728222.2025.2464173","article-title":"Therapeutic targeting of the polyglutamine androgen receptor in spinal and bulbar muscular atrophy","volume":"29","author":"Sangotra","year":"2025","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.neurot.2025.e00732_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(10)70182-4","article-title":"Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"9","author":"Katsuno","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00732_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116166","article-title":"Annual review of PROTAC degraders as anticancer agents in 2022","volume":"267","author":"Wang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00732_bib9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers16030663","article-title":"Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.neurot.2025.e00732_bib10","unstructured":"Arvinas Inc. A phase 1\/2, open-label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration resistant prostate cancer [Internet]. clinicaltrials.gov; 2025 Mar. Report No.: NCT03888612. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03888612."},{"key":"10.1016\/j.neurot.2025.e00732_bib11","year":"2025"},{"key":"10.1016\/j.neurot.2025.e00732_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2353\/ajpath.2006.050619","article-title":"Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG Knock-In mice reveal toxic effects of the mutant protein","volume":"168","author":"Yu","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurot.2025.e00732_bib13","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1172\/JCI28773.","article-title":"Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model","volume":"116","author":"Yu","year":"2006","journal-title":"J Clin Investig"},{"key":"10.1016\/j.neurot.2025.e00732_bib14","doi-asserted-by":"crossref","first-page":"50855","DOI":"10.1074\/jbc.M209466200","article-title":"Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy","volume":"277","author":"Walcott","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurot.2025.e00732_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cpcb.51","article-title":"Transcription-factor mediated differentiation of human iPSCs into neurons","volume":"79","author":"Fernandopulle","year":"2018","journal-title":"Curr Protoc Cell Biol"},{"key":"10.1016\/j.neurot.2025.e00732_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2014.05.038","article-title":"Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients","volume":"70","author":"Grunseich","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00732_bib17","doi-asserted-by":"crossref","first-page":"13280","DOI":"10.1021\/acs.jmedchem.3c01264","article-title":"Discovery of ARD-1676 as a highly potent and orally efficacious AR PROTAC degrader with a broad activity against AR mutants for the treatment of AR + human prostate cancer","volume":"66","author":"Xiang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00732_bib18","doi-asserted-by":"crossref","first-page":"13487","DOI":"10.1021\/acs.jmedchem.1c00900","article-title":"Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer","volume":"64","author":"Xiang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00732_bib19","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","article-title":"Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer","volume":"64","author":"Han","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00732_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet.journal"},{"key":"10.1016\/j.neurot.2025.e00732_bib21","unstructured":"Babraham bioinformatics - FastQC A quality control tool for high throughput sequence data [Internet]. [cited 2025 May 6]. Available from: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"10.1016\/j.neurot.2025.e00732_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neurot.2025.e00732_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.neurot.2025.e00732_bib24","unstructured":"STAR\/doc\/STARmanual.pdf at master \u00b7 alexdobin\/STAR [Internet]. GitHub. [cited 2025 May 6]. Available from: https:\/\/github.com\/alexdobin\/STAR\/blob\/master\/doc\/STARmanual.pdf."},{"key":"10.1016\/j.neurot.2025.e00732_bib25","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neurot.2025.e00732_bib26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.neurot.2025.e00732_bib27","doi-asserted-by":"crossref","first-page":"W305","DOI":"10.1093\/nar\/gkp427","article-title":"ToppGene suite for gene list enrichment analysis and candidate gene prioritization","volume":"37","author":"Chen","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurot.2025.e00732_bib28","article-title":"Linking epigenetic dysregulation, mitochondrial impairment, and metabolic dysfunction in SBMA motor neurons [Internet]","author":"Pourshafie","year":"2020","journal-title":"Am Soc Clin Investig"},{"key":"10.1016\/j.neurot.2025.e00732_bib29","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1021\/jm201059s","article-title":"Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists","volume":"54","author":"Guo","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2025.e00732_bib30","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70341","article-title":"iMyoblasts for ex vivo and in vivo investigations of human myogenesis and disease modeling","volume":"11","author":"Guo","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.neurot.2025.e00732_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.celrep.2014.02.008","article-title":"Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy","volume":"7","author":"Lieberman","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.neurot.2025.e00732_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.neuron.2014.03.001","article-title":"Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy","volume":"82","author":"Cortes","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neurot.2025.e00732_bib33","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1073\/pnas.0705501104","article-title":"Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease","volume":"104","author":"Monks","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.neurot.2025.e00732_bib34","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1212\/WNL.0000000000007097","article-title":"Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy","volume":"92","author":"Lombardi","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00732_bib35","doi-asserted-by":"crossref","unstructured":"Tebbenkamp ATN, Huggett SB, Lombardi V, Zampedri L, AlQahtani A, Kokkinis A, et al. Protein biomarker signature in patients with spinal and bulbar muscular atrophy. JCI Insight. 9:e176383.","DOI":"10.1172\/jci.insight.176383"},{"key":"10.1016\/j.neurot.2025.e00732_bib36","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1007\/s00018-016-2275-1","article-title":"Polyglutamine androgen receptor-mediated neuromuscular disease","volume":"73","author":"Giorgetti","year":"2016","journal-title":"Cell Mol Life Sci"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:45:35Z","timestamp":1772894735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1878747925002107"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00732","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PROTACs therapeutically target the polyglutamine androgen receptor in spinal and bulbar muscular atrophy models","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00732"}}